Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using liquid biopsies and breath samples to detect lung cancer mutations

Official title: A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer

Run by St. Joseph's Healthcare Hamilton · NCT06707519 · Data updated 2026-11-12

This study is testing if using samples from blood, sputum, and breath can help find lung cancer mutations in patients with non-small cell lung cancer before and after surgery.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment210 (estimated)
SponsorSt. Joseph's Healthcare Hamilton
Academic / other
Locations1 site (Hamilton, Ontario)
StatusRecruiting
StartedFebruary 1, 2023
Main results expectedDecember 29, 2027
Study endsDecember 29, 2027
Registry record updatedApril 22, 2026
Trial IDNCT06707519 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old who are undergoing surgical resection with curative intent for NSCLC-adenocarcinoma.

Probably not a fit

Patients with non-curative surgical resections, metastatic disease, or other malignancies may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the feasibility of recruiting participants and utilizing various biological samples, including sputum, bronchoalveolar lavage (BAL), and exhaled volatile organic compounds (VOC), alongside blood, to detect mutations in cell-free DNA in patients with non-small cell lung cancer (NSCLC). The study will follow patients undergoing surgical resection for NSCLC-adenocarcinoma, collecting samples at multiple time points before and after surgery, as well as during follow-up visits over a 24-month period. The goal is to evaluate the potential of these samples as novel biomarkers for monitoring disease recurrence and treatment response.

Why it matters

Potential benefit: If successful, this study could improve early detection of lung cancer recurrence and enhance monitoring of treatment responses.

How similar studies have gone: While the use of ctDNA in blood for cancer detection has shown promise, the validation of sputum and BAL samples for this purpose is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient must be at least 18 years of age
* Patient must be able to provide consent
* Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.

Exclusion Criteria:

* Resection done with non-curative intent or metastatic disease
* other malignancies
* Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).

Where it's running

  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.